Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases

NCT03339089 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03339089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03339089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
May 18, 2018
Completion date
July 8, 2021
Enrollment
224 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis (as), psoriasis, rheumatoid arthritis (ra)